Selective Termination of Autophagy-Dependent Cancers

The goal of Cancer research is to identify characteristics of Cancer cells that allow them to be selectively eliminated without harming the host. One such characteristic is Autophagy dependence. Cancer cells survive, proliferate, and metastasize under conditions where normal cells do not. Thus, the requirement in Cancer cells for more energy and macromolecular biosynthesis can evolve into a dependence on Autophagy for recycling cellular components. Recent studies have revealed that Autophagy, as well as different forms of cellular trafficking, is regulated by five phosphoinositides associated with eukaryotic cellular membranes and that the Enzymes that synthesize them are prime targets for Cancer therapy. For example, PIKfyve inhibitors rapidly disrupt lysosome homeostasis and suppress proliferation in all cells. However, these inhibitors selectively terminate PIKFYVE-dependent Cancer cells and Cancer Stem Cells with not having adverse effect on normal cells. Here, we describe the biochemical distinctions between PIKFYVE-sensitive and -insensitive cells, categorize PIKfyve inhibitors into four groups that differ in chemical structure, target specificity and efficacy on Cancer cells and normal cells, identify the mechanisms by which they selectively terminate autophagy-dependent Cancer cells, note their paradoxical effects in Cancer Immunotherapy, and describe their therapeutic applications against cancers.

PIKFYVE; PIP4K2C; PIP5K1C; apoptosis; autophagy; cancer; endoplasmic reticulum stress.